Metformin
First-line type 2 diabetes therapy studied for geroprotection.
Notify me when meaningful evidence changes.
0
Insufficient evidence · Stable
No history yet
⚠ Prescription or off-label use
Approved for diabetes, not for ageing. Use for longevity is off-label and unproven.
Current assessment
Observational data suggesting mortality benefit in diabetics compared to non-diabetics has been challenged on methodological grounds. The TAME trial is designed to test the ageing hypothesis directly.
- Regulatory status
- Approved other indication
- Availability
- Prescription only
- Category
- Experimental off label
- Human studies tracked
- 0
Evidence breakdown
Human evidence
0
Animal evidence
0
Mechanistic
0
Safety
50
What changed
Evidence events affecting this intervention
No published evidence events yet
Evidence timeline
Every recorded score change
No score history yet
Major human studies
No human studies tracked yet
Animal and mechanistic evidence
No preclinical studies tracked yet